Cover Image

Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy

Saved in:
Bibliographic Details
Main Authors: Döhner, Hartmut (Author) , Lübbert, Michael (Author) , Fiedler, Walter (Author) , Fouillard, Loic (Author) , Haaland, Alf (Author) , Brandwein, Joseph M. (Author) , Lepretre, Stephane (Author) , Reman, Oumedaly (Author) , Turlure, Pascal (Author) , Ottmann, Oliver G. (Author) , Müller-Tidow, Carsten (Author) , Krämer, Alwin (Author) , Raffoux, Emmanuel (Author) , Döhner, Konstanze (Author) , Schlenk, Richard F. (Author) , Voß, Florian (Author) , Taube, Tillmann (Author) , Fritsche, Holger (Author) , Maertens, Johan (Author)
Format: Article (Journal)
Language:English
Published: August 2014
In: Blood
Year: 2014, Volume: 124, Issue: 9, Pages: 1426-1433
ISSN:1528-0020
DOI:10.1182/blood-2014-03-560557
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/blood-2014-03-560557
Verlag, Volltext: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4148765/
Get full text
Author Notes:Hartmut Döhner, Michael Lübbert, Walter Fiedler, Loic Fouillard, Alf Haaland, Joseph M. Brandwein, Stephane Lepretre, Oumedaly Reman, Pascal Turlure, Oliver G. Ottmann, Carsten Müller-Tidow, Alwin Krämer, Emmanuel Raffoux, Konstanze Döhner, Richard F. Schlenk, Florian Voss, Tillmann Taube, Holger Fritsch, and Johan Maertens
Description
Item Description:Gesehen am 27.07.2020
Physical Description:Online Resource
ISSN:1528-0020
DOI:10.1182/blood-2014-03-560557

Similar Items